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Abstract 16	
Primary	Coenzyme	Q	deficiencies	represent	a	group	of	rare	conditions	caused	by	mutations	in	17	
one	of	the	genes	required	in	its	biosynthetic	pathway	at	the	enzymatic	or	regulatory	level.	The	18	
associated	 clinical	 manifestations	 are	 highly	 heterogeneous	 and	 mainly	 affect	 central	 and	19	
peripheral	 nervous	 system,	 kidney,	 skeletal	 muscle	 and	 heart.	 Genotype-phenotype	20	
correlations	are	difficult	 to	establish,	mainly	because	of	 the	reduced	number	of	patients	and	21	
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the	 large	 variety	 of	 symptoms.	 In	 addition,	 mutations	 in	 the	 same	 COQ	 gene	 can	 cause	22	
different	 clinical	 pictures.	 Here	 we	 present	 an	 updated	 and	 comprehensive	 review	 of	 the	23	
clinical	 manifestations	 associated	 to	 each	 of	 the	 pathogenic	 variants	 causing	 primary	 CoQ	24	
deficiencies.	25	
Abbreviation l ist  26	
2,4-dHB,	 2,4-dihydroxybenzoic	 acid;	 3,4-dHB,	 3,4-dihydroxybenzoate;	 4-HB,	 4-27	
hydrozybenzoate;	 CNS,	 central	 nervous	 system;	 CoQ,	 Coenzyme	 Q;	 EEG,	28	
electroencephalography;	 ESRD,	 end-stage	 renal	 disease;	 ETFDH,	 electron	 transport	29	
flavoprotein	dehydrogenase;	HHB,	hexaprenyl-hydroxybenzoate;	ID,	intellectual	disability;	LDL,	30	
low	 density	 lipoproteins;	 mETC,	 mitochondrial	 electron	 transport	 chain;	 MRI,	 magnetic	31	
resonance	 imaging;	OXPHOS,	oxidative	phosphorylation;	pABA,	para-aminobenzoic	acid;	PNS,	32	
peripheral	 nervous	 system;	 ROS,	 reactive	 oxygen	 species;	 SNHL,	 sensorineural	 hearing	 loss;	33	
SRNS,	steroid-resistant	nephrotic	syndrome;	VA,	vanillic	acid.		34	
Please,	refer	to	table	3	for	symptoms	abbreviations.	35	
Coenzyme Q structure and function 36	
Coenzyme	Q	(CoQ)	or	ubiquinone	is	the	only	endogenously	synthetized	redox-active	lipid	that	37	
is	 found	 in	 virtually	 all	 endomembranes,	 plasma	 membrane	 and	 serum	 lipoproteins,	 being	38	
especially	abundant	in	mitochondria.	It	 is	composed	of	a	benzoquinone	ring	as	a	head	group,	39	
and	a	polyisoprenoid	chain,	which	inserts	the	molecule	into	the	phospholipid	bilayer	and	varies	40	
in	length	depending	on	the	species	(figure	1A).	In	humans,	it	has	10	isoprene	units	(CoQ10),	6	in	41	
Saccharomyces	cerevisiae	(CoQ6)	and	the	main	form	found	in	mice	has	9	units	(CoQ9),	although	42	
low	amounts	of	CoQ10	can	be	also	detected	in	their	membranes.		43	
Soon	after	the	first	description	by	Cain	and	Morton	in	1955	(1),	the	main	function	of	CoQ	in	the	44	
mitochondrial	 electron	 transport	 chain	 (mETC)	 was	 proposed	 by	 Crane	 and	 cols.,	 who	 also	45	
demonstrated	 its	 redox	 proprieties	 (2).	 In	 the	 mETC	 CoQ	 is	 an	 essential	 mobile	 electron	46	
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transport	component,	 shuttling	electrons	 from	complex	 I	 (NADH-ubiquinone	oxidoreductase)	47	
or	 complex	 II	 (succinate-ubiquinone	 oxidoreductase)	 to	 complex	 III	 (succinate-cytochrome	 c	48	
oxidoreductase).		49	
CoQ	is	permanently	going	through	oxidation-reduction	cycles.	It	can	be	found	in	a	completely	50	
reduced	form	(CoQH2	or	ubiquinol),	after	receiving	two	electrons,	or	in	a	completely	oxidized	51	
form	 (CoQ	 or	 ubiquinone).	 When,	 as	 in	 the	 mETC,	 this	 redox	 cycle	 occurs	 by	 a	 two-step	52	
transfer	 of	 one	 electron	 each,	 a	 semiquinone	 (or	 semi-ubiquinone,	 CoQ•-)	 intermediate	 is	53	
produced	(figure	1B).	54	
Computational	prediction	models	have	recently	confirmed	studies	describing	how,	in	the	inner	55	
mitochondrial	 membrane,	 CoQ	 is	 mainly	 located	 either	 close	 to	 the	 membrane-water	56	
interface,	with	 its	 relatively	 small	 head	 group	 being	 shadowed	 by	 the	 bigger	 polar	 heads	 of	57	
phospholipids,	 or	 stabilized	 in	 the	 middle	 of	 the	 bilayer.	 During	 the	 process	 of	 electron	58	
transfer,	CoQ	rapidly	translocates	from	one	side	to	the	other	of	the	inner	membrane	bilayer,	59	
with	a	rate	that	varies	depending	on	the	redox	state	of	the	molecule.	This	process	enables	the	60	
interaction	 with	 the	 reducing	 and	 oxidizing	 sites	 in	 the	 proteins	 of	 the	 mETC	 complexes,	61	
located	close	to	the	membrane	surfaces	(3).	62	
After	 the	discovery	of	 its	 role	 in	 the	mETC,	new	 functions	have	emerged	 for	CoQ,	being	 the	63	
electron	acceptor	 for	different	dehydrogenases.	Among	others,	 in	mitochondria	CoQ	accepts	64	
electrons	from:		65	
(i) dihydroorotate	dehydrogenase,	a	key	enzyme	for	pyrimidine	biosynthesis	(4)	,		66	
(ii) mitochondrial	 glycerol-3-phosphate	 dehydrogenase	 (5),	 a	 tissue-specific	67	
component	of	mitochondria	connecting	glycolysis,	oxidative	phosphorylation	and	68	
fatty	acid	metabolism		(6),	69	
(iii) electron	transport	flavoprotein	dehydrogenase	(ETFDH),	a	key	enzyme	involved	in	70	
the	fatty	acid	β-oxidation	and	branched-chain	amino	acid	oxidation	pathways	(7),	71	
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(iv) proline	dehydrogenase	1,	an	enzyme	required	for	proline	and	arginine	metabolism	72	
(8),		73	
(v) probably,	 from	 hydroxyproline	 dehydrogenase	 (or	 proline	 dehydrogenase	 2),	74	
involved	in	the	glyoxylate	metabolism		(9)	75	
(vi) sulphide-quinone	 oxidoreductase	 (10)	 during	 sulphide	 detoxification,	 a	 gas	76	
modulator	of	relevant	cellular	processes	but	toxic	when	in	excess		(11).			77	
Reduced	CoQ	(CoQH2)	generated	by	all	these	processes	is	efficiently	reoxidised	by	complex	III	78	
in	the	mETC	(figure	1C).		79	
The	 ability	 to	 sustain	 continuous	 oxidation/reduction	 cycles	 makes	 CoQ	 not	 only	 a	 great	80	
electron	 carrier	 for	 different	 cellular	 processes,	 but	 also	 a	 potent	 membrane	 antioxidant,	81	
which	 protects	 lipids,	 proteins	 and	 nucleic	 acids	 from	harmful	 oxidative	 damage	 	 (12,13).	 In	82	
membranes,	 CoQH2	 has	 been	 shown	 to	 prevent	 both	 initiation	 and	 propagation	 of	 lipid	83	
peroxidation	 (14,15)	 and,	 indirectly,	 to	 regenerate	 other	 antioxidants,	 such	 as	 α-tocopherol	84	
and	ascorbate	 (16).	 	The	high	efficiency	of	CoQ	against	oxidative	stress	may	be	related	to	 its	85	
ubiquitous	distribution,	its	localization	in	the	core	of	membranes	and	the	availability	of	diverse	86	
dehydrogenases,	able	to	efficiently	regenerate	the	molecule.	87	
CoQ biosynthesis and regulation in eukaryotes/human 88	
Levels	of	CoQ	are	quite	stable	in	cells	but	its	concentration	varies	among	different	tissues	and	89	
organs,	 depending	 on	 dietary	 conditions	 and	 age	 (17–20).	 Although	 CoQ	 is	 mainly	90	
endogenously	synthetized	in	mitochondria	and	then	distributed	to	other	cell	membranes	(21),	91	
cells	 can	 incorporate	 a	 certain	 amount	 from	dietary	 sources.	 CoQ	 is	 synthesized	 by	 a	 set	 of	92	
nuclear-encoded	COQ	proteins,	through	a	pathway	that	is	not	completely	understood.	Most	of	93	
the	 work	 on	 CoQ	 biosynthesis	 has	 been	 done	 in	 Saccharomyces	 cerevisiae,	 and	 at	 least	 13	94	
yeast	 genes	 (coq1	 –	 coq11,	 Yah1,	 Arh1)	 have	 been	 identified	 as	 players	 of	 this	 process.	95	
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Information	about	 the	human	pathway	 is	very	 scarce,	but	orthologues	of	almost	all	of	 these	96	
genes	have	been	already	identified	(see	Dr.	Clark	review	in	this	same	number).		97	
4-Hydrozybenzoate	 (4-HB),	precursor	of	 the	benzoquinone	ring,	 is	 synthesized	 from	tyrosine,	98	
phenylalanine,	or	also	para-aminobenzoic	acid	(pABA)	in	yeast,	through	a	poorly	characterized	99	
set	 of	 reactions	 (22–24).	 The	 isoprenoid	 tail	 comes	 from	 the	mevalonate	 pathway,	which	 is	100	
shared	 with	 cholesterol,	 among	 other	 molecules,	 and	 takes	 place	 in	 extra-mitochondrial	101	
membranes.	 This	 side	 chain	 is	 assembled	 by	 Coq1p	 (PDSS1	 and	 PDSS2,	 acting	 as	 a	102	
heterotetramer,	are	the	human	orthologues),	which	also	determines	its	length.	Coq2p	(human	103	
orthologue	 COQ2)	 condensates	 head	 and	 tail	 and	 the	 resulting	 molecule	 undergoes	104	
subsequent	modifications	 of	 the	 ring	moiety:	 C5-hydroxylation	 (yeast	 Coq6p,	 human	 COQ6)	105	
(25),	 O-methylations	 (yeast	 Coq3p,	 human	 COQ3)	 (26,27),	 C1-hydroxylation	 and	 C1-106	
decarboxylation	 (unidentified),	 C2-methylation	 (yeast	 Coq5p,	 human	COQ5)	 (28,29),	 and	C6-107	
hydroxylation	(yeast	Coq7p,	human	COQ7)	(30),	but	also	C4-deamination	(Coq6p),	in	the	case	108	
of	yeast	using	pABA	as	precursor	 (24).	Yah1	and	Arh1	 (human	orthologues,	FDXR	and	FDX2),	109	
mitochondrial	ferredoxin	and	ferredoxin	reductase,	have	been	shown	to	transfer	electrons	to	110	
Coq6p	 (31).	 Mammalian	 pathway	 is	 still	 incompletely	 defined	 and	 significant	 efforts	 are	111	
required	in	order	to	determine	whether	it	coincides	with	the	yeast	one	(figure	2).	112	
Other	Coq	proteins	are	thought	to	have	regulatory	functions.	Coq8p	(two	human	orthologues:	113	
COQ8A	(or	ADCK3/CABC1)	and	COQ8B	(or	ADCK4)),	displays	features	of	an	atypical	kinase	that	114	
possibly	phosphorylates	Coq3p,	Coq5p	and	Coq7p	 in	yeast	 (32–34).	However,	COQ8A/ADCK3	115	
has	 recently	 been	 shown	 to	 have	 a	 more	 clear	 ATPase	 activity	 (35)	 whose	 role	 in	 CoQ	116	
biosynthesis	 still	needs	 to	be	 further	 studied.	Coq4p	 (human	orthologue	COQ4)	 function	has	117	
not	been	elucidated	yet,	but	it	seems	to	be	required	for	the	formation	and	maintenance	of	the	118	
CoQ	 biosynthetic	 complex	 (36).	 Coq9p	 (human	 orthologue	 COQ9)	 is	 a	 lipid-binding	 protein	119	
stabilizing	 Coq7p	 (37,38).	 Coq10p	 (human	 orthologues	 COQ10A	 and	 COQ10B)	 probably	120	
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controls	CoQ	correct	localization	within	the	mitochondrial	membranes	(39).	Coq11p	is	thought	121	
to	 be	 essential	 for	 CoQ	 synthesis	 in	 yeast,	 but	 lacks	 a	 clear	 human	 orthologue	 (40).	122	
Additionally,	 three	other	genes	of	 the	ADCK	 family	 (human	ADCK1,	ADCK2	 and	ADCK5)	have	123	
been	 proposed	 to	 participate	 in	 the	 biosynthetic	 process,	 but	 there	 is	 no	 experimental	124	
evidence	for	this	(34,41).	125	
It	is	widely	accepted	that	yeast	Coq3p-Coq9p	proteins	are	organized	in	a	multiprotein	complex,	126	
possibly	 containing	 some	 intermediates	 of	 the	 biosynthesis	 and	 CoQ	 itself	 (40,42,43).	 The	127	
complex	 would	 probably	 optimize	 the	 orientation	 of	 the	 substrates	 and	 active	 sites	 of	 the	128	
enzymes	as	well	as	their	functional	coordination	(36,44–47)	(figure	2).	Evidence	supporting	the	129	
existence	 of	 a	 conserved	 complex	 also	 in	mammals	 has	 been	 recently	 reported	 by	 different	130	
groups	through	diverse	approaches	(23,29,35,38,48–52).	However,	functional	organization	and	131	
regulation	of	mammalian	biosynthetic	complex	is	still	elusive	and	could	be	different	from	the	132	
yeast	one.		133	
Little	 is	 known	 about	 CoQ	 biosynthesis	 regulation,	 which	 may	 occur	 at	 the	 transcriptional,	134	
post-transcriptional	and	post-translational	 level,	or	even	during	 the	assembly	of	 the	putative	135	
multisubunit	complex.	Transcriptionally,	 several	 factors	have	emerged	as	possible	candidates	136	
(53–55).	However,	a	deep	study	of	promoters	and	regulation	sequences	of	 the	COQ	genes	 is	137	
lacking	currently.	At	the	post-transcriptional	level,	several	RNA	binding	proteins	that	modulate	138	
the	 stability	 of	 COQ	 transcripts	 have	 also	 been	 identified	 (56,57).	 	 At	 the	 post-translational	139	
level,	processing	by	proteases,	phosphorylation	and	dephosphorylation	have	been	suggested	140	
to	 have	 a	 role	 in	 the	 regulation	of	 some	COQ	proteins’	 activity,	 but	 only	 a	 very	 fragmented	141	
piece	of	information	is	currently	available	(33,34,58,59).		142	
Clinical  manifestations of CoQ deficiencies.   143	
CoQ	deficiencies	have	been	associated	with	a	wide	 range	of	 clinical	manifestations.	 Patients	144	
with	 CoQ	 deficiency	 have	 reduced	 levels	 of	 CoQ	 in	 tissues,	 which	 can	 be	 caused	 either	 by	145	
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mutations	 in	 the	 genes	 participating	 in	 CoQ	 biosynthesis,	 the	 so-called	 primary	 CoQ	146	
deficiencies,	 or	 by	 defects	 not	 directly	 linked	 CoQ	 biosynthesis,	 the	 secondary	 CoQ	147	
deficiencies.			148	
Primary deficiencies.   149	
Primary	 CoQ	 deficiencies	 are	 very	 rare	 conditions,	 usually	 associated	 with	 highly	 variable	150	
multisystemic	 manifestations	 (figure	 3),	 and	 genetically	 caused	 by	 autosomal	 recessive	151	
mutations.	Approximately	200	patients	from	130	families	have	been	described	in	the	literature	152	
so	far	(Supplementary	Table	1).		153	
It	 has	 been	 estimated	 a	 worldwide	 total	 of	 123,789	 individuals	 (1	 in	 50,000)	 affected	 by	154	
primary	CoQ	deficiencies,	being	only	1,665	(less	than	1	in	3,000,000)	due	to	known	pathogenic	155	
variants,	 taking	 into	 account	 the	 frequency	 of	 the	 different	 known	 or	 predicted	 pathogenic	156	
variants	in	given	populations	(60).		157	
To	date,	ten	genes	encoding	CoQ	biosynthetic	proteins	have	been	shown	to	have	pathogenic	158	
variants	 causing	 human	 CoQ	 deficiency:	 PDSS1,	 PDSS2,	 COQ2,	 COQ4,	 COQ5,	 COQ6,	 COQ7,	159	
COQ8A,	 COQ8B	 and	 COQ9	 (Table	 1,	 supplementary	 table	 1).	 They	 affect	 multiple	 organ	160	
systems	 in	 a	 highly	 variable	 way,	 including	 central	 nervous	 system	 (CNS)	 (encephalopathy,	161	
seizures,	 cerebellar	 ataxia,	 epilepsy	 or	 intellectual	 disability	 (ID)),	 peripheral	 nervous	 system	162	
(PNS),	kidney	(steroid-resistant	nephrotic	syndrome	(SRNS)),	skeletal	muscle	(myopathy),	heart	163	
(hypertrophic	 cardiomyopathy)	 and	 sensory	 system	 (sensorineural	 hearing	 loss	 (SNHL),	164	
retinopathy	 or	 optic	 atrophy)	 (Table	 2).	 While	 mutations	 in	 some	 COQ	 genes	 can	 affect	165	
different	 organs	 (e.g.	 COQ2,	 COQ4),	 pathogenic	 variants	 of	 other	 COQ	 genes	 show	 a	 more	166	
specific	 phenotype	 (e.g.	COQ8A,	COQ8B).	 Even	more,	mutations	 in	 the	 same	COQ	 gene	 can	167	
cause	 very	 variable	 clinical	 phenotypes	 with	 different	 age	 of	 onset.	 The	 age	 of	 onset	 may	168	
generally	 range	 from	 birth	 to	 early	 childhood	 (PDSS1,	 PDSS2,	 COQ2,	 COQ4,	 COQ5,	 COQ6,	169	
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COQ7,	COQ9),	 or	 from	 childhood	 to	 adolescence	 (COQ8A,	COQ8B),	 but	 there	 are	 also	 some	170	
adult-onset	cases	(COQ2	(61);	COQ8A	(62,63);	COQ8B	(64)).	171	
CNS manifestations: 172	
Central	 nervous	 system	 is	 often	 affected	 in	 these	 patients,	 showing	 a	wide	 range	 of	 clinical	173	
manifestations,	 including	 encephalopathy,	 hypotonia,	 seizures,	 dystonia,	 cerebellar	 ataxia,	174	
epilepsy,	 stroke-like	 episodes,	 spasticity	 or	 ID.	 These	 symptoms	may	 be	 present	 in	 patients	175	
with	mutations	in	one	of	the	reported	COQ	genes,	but	they	are	less	prominent	in	patients	with	176	
pathogenic	 variants	 of	 COQ6	 and	 COQ8B,	 in	 whom	 the	 more	 frequent	 phenotype	 is	 renal	177	
involvement.	 COQ2	 patients	 manifested	 early-onset	 nephrotic	 syndrome	 (17/22)	 which	 in	178	
some	 cases	 may	 be	 accompanied	 by	 encephalopathy	 and	 seizures	 (7/22)	 (65–76).	 COQ4	179	
patients	generally	show	a	severe	CNS	 involvement,	with	encephalopathy	and	seizures	(9/14),	180	
hypotonia	 (10/14)	and	cerebellar	hypoplasia	 (6/14);	and	often	a	 fatal	outcome	with	death	 in	181	
the	 first	 days	 (6/14)	 or	 months	 (5/14)	 of	 life	 (77–81).	 The	 hallmark	 phenotype	 in	 COQ8A	182	
patients	is	slow	progressive	cerebellar	atrophy	and	ataxia	(43/45),	associated	with	ID	(19/45),	183	
epileptic	 seizures	 (18/45),	 tremor	 (18/45),	 dysarthria	 (16/45),	 saccadic	 eye	 movements	184	
(10/45),	 dystonia	 (9/45)	 or	 spasticity	 (8/45),	 among	 others	 (62,63,82–93).	 The	 only	 COQ5	185	
family	 described	 shows	 a	 phenotype	 similar	 to	 COQ8A	 patients	 (94).	 Some	 COQ8A	 patients	186	
(6/45)	 (62,84,85,87)	and	one	COQ2	patient	 (1/19)	 (66)	 suffered	one	stroke-like	episode,	 that	187	
contributed	 significantly	 to	 deterioration	 of	 the	 neurological	 status	 and	 may	 explain	 the	188	
heterogeneity	 of	 the	 functional	 outcome	 among	 affected	 siblings	 (84).	 Some	COQ2	 variants	189	
have	also	been	predicted	to	increase	susceptibility	to	adult-onset	multisystem	atrophy	(MSA),	190	
but	this	issue	is		still	under	debate	(61,95).	191	
Very	 few	 patients	 with	 mutations	 in	 PDSS1	 (70,96),	 PDSS2	 (71,97–100),	 COQ5	 (94),	 COQ7	192	
(101,102)	and	COQ9	(103–106)	have	been	 identified	to	define	a	specific	phenotype,	but	they	193	
presented	encephalopathy	(PDSS1,	COQ9),	Leigh-like	syndrome	(PDSS2,	COQ9),	ataxia	(PDSS2,	194	
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COQ5),	 ID	 (PDSS1,	PDSS2,	COQ5,	COQ7),	 seizures	 (PDSS2,	COQ5,	COQ9)	 or	 spasticity	 (PDSS2,	195	
COQ5,	COQ7).	196	
Peripheral nervous system and sensory organs manifestations: 197	
Peripheral	neuropathy	has	been	described	in	2	siblings	with	PDSS1	mutations,	associated	with	198	
optic	 atrophy	 and	 early-onset	 SNHL	 (70).	 Also,	 the	 2	 COQ7	 patients	 described	 showed	199	
peripheral	 polyneuropathy,	 again	 with	 SNHL	 and	 one	 of	 them	 with	 visual	 dysfunction	200	
(101,102).	 SNHL	 is	 very	 frequent,	 especially	 in	 COQ6	 patients	 (16/26)	 (69,71,107–109),	201	
associated	 with	 SRNS	 in	 all	 cases,	 and	with	 optic	 atrophy	 (1/18)	 (109).	 One	 COQ8A	 patient	202	
(1/45)	 also	 showed	 early-onset	 bilateral	 SNHL	 (82–84),	 as	 well	 as	 patients	 with	 PDSS2	203	
mutations	 (4/7),	 who	 manifested	 retinitis	 pigmentosa	 (2/7)	 and	 optic	 atrophy	 (1/7),	 too	204	
(98,100).	 One	 patient	 with	COQ4	 mutations	 (1/14)	manifested	 bilateral	 hearing	 loss	 as	 well	205	
(77).	Visual	impairment	was	also	a	symptom	in	some	patients	with	optic	atrophy	(PDSS1	(70),	206	
PDSS2	(98,100),	COQ2	(66),	COQ6	(109)),	retinopathy	(COQ2)	(74),	retinitis	pigmentosa	(PDSS2	207	
(100),	COQ2	(61),	COQ8B	(110))	and	cataracts	(PDSS2	(98),	COQ8A	(62)).	208	
Renal manifestations: 209	
SRNS	 is	 frequent	 in	 primary	CoQ	deficiency	 patients,	 specifically	 in	 patients	with	 pathogenic	210	
variants	of	COQ2,	COQ6	and	COQ8B.	It	generally	starts	as	proteinuria	and	if	untreated	evolves	211	
to	end-stage	renal	disease	(ESRD)	within	childhood	(71).		212	
COQ2	patients	displayed	early-onset	nephrotic	syndrome	(15/22)	(65–68,70,71,73,76),	isolated	213	
(9/22)	or	with	encephalopathy	and	seizures	(6/22),	but	there	was	also	one	family	with	onset	in	214	
adolescence,	slow	progression	of	the	renal	disease	and	mild	neurological	symptoms	(69).	The	215	
hallmark	of	COQ6	pathogenic	variants	 is	childhood-onset	SNRS	 (23/26)	associated	with	SNHL	216	
(16/26)	 (69,71,107–109,111).	 COQ8B	 patients	 mainly	 presented	 with	 an	 adolescence-onset	217	
SRNS	 due	 to	 focal	 segmental	 glomerulosclerosis,	 associated	 with	 edema	 (15/74)	 and	218	
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hypertension	(10/74),	which	generally	progressed	to	ESRD	(50,64,110,112–116).	Onset	of	SRNS	219	
may	be	before	10	years	of	age	(29/74).	220	
Patients	with	PDSS1	(1/3)	(96)	and	PDSS2	(7/7)	(71,97–100)mutations	also	showed	SRNS.	One	221	
COQ9	(1/6)	(104)	and	one	COQ2	(1/22)	(75)	patient	displayed	a	tubulopathy.		222	
Muscle manifestations: 223	
Isolated	myopathy	has	not	been	found	in	individuals	with	molecularly	confirmed	primary	CoQ	224	
deficiency.	The	majority	of	the	patients	with	a	predominantly	muscular	phenotype	have	been	225	
associated	 with	 secondary	 CoQ	 deficiency.	 Myopathy	 has	 been	 described	 in	 some	 patients	226	
with	 a	 multisystemic	 phenotype	 (COQ4	 (1/14)	 (81),	 COQ8A	 (1/45)	 (91)).	 Other	 muscular	227	
manifestations	 include	 exercise	 intolerance	 (COQ8A	 (8/45)	 (82,84–86)),	 muscle	 weakness	228	
(COQ2	 (1/22)	 (66),	 COQ6	 (2/26)	 (109),	 COQ7	 (2/2)	 (101,102),	 COQ8A	 (7/45)	 (62,85,87,92),	229	
COQ8B	(1/74)	(113))	and	muscle	fatigue	(COQ8A	(2/45)	(62,90)	and	COQ8B	(1/74)	(110)).	Some	230	
muscle	 biopsies	 have	 shown	 lipid	 accumulation	 in	muscle	 (COQ4	 (1/14)	 (81),	COQ8A	 (3/45)	231	
(62,85),	COQ2	(1/22)	(72)).	232	
Cardiac manifestations: 233	
The	most	frequent	heart	manifestation	is	hypertrophic	cardiomyopathy,	often	present	in	COQ4	234	
patients	with	a	prenatal	onset	(7/14)	(77–79),	whereas	COQ2	(3/22)	(65,72,75),	COQ8B	(2/74)	235	
(64,112,113),	COQ7	 (1/2)	 (101)	and	COQ9	patients	 (1/6)	 (104)	 show	a	neonatal	onset.	Other	236	
less	 frequently	 reported	 cardiac	 manifestations	 are	 valvulopathies	 (PDSS1	 (2/3)	 (70)),	 heart	237	
hypoplasia	 (COQ4	 (1/14)	 (78)),	 septal	 defects	 (COQ4	 (1/14)	 (81),	 COQ8B	 (2/74)	 (110,116)),	238	
heart	failure	(COQ4	(2/14)	(78,79)	and	COQ8B	(1/74)	(110)),	bradycardia	(COQ4	(4/14)	(77–79),	239	
COQ9	 (2/6)	 (105,106),	 or	 pericardial	 effusion	 (COQ8B	 (1/74)	 (64,112)).	 However,	 it	 is	240	
questionable	 whether	 some	manifestations	 such	 as	 heart	 failure,	 bradycardia	 or	 pericardial	241	
effusion	 are	 primary	 events	 or	 are	 secondary	 manifestations	 of	 some	 other	 general	242	
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phenomena.	243	
	244	
Other manifestations: 245	
Less	 frequent	 clinical	 findings	 include	 dysmorphic	 features	 (81,107),	 metabolic	 pathologies	246	
(diabetes	mellitus	(70,75),	obesity	(70)	and	hypercholesterolemia	(69,113)	-although	the	latest	247	
is	 often	 observed	 during	 SRNS,	 independently	 of	 its	 aetiology-),	 thyroid	 disease	 (goiter	248	
(50,112),	hypothyroidism	(64)),	 lung	involvement	(respiratory	distress	-very	frequent	in	COQ4	249	
patients	 (9/14)	 (75,78,79,101,105)-,	 apnea	 (74,77–79,105)	 or	 respiratory	 failure	250	
(66,74,75,77,78)),	 circulatory	 problems	 (cyanosis	 (78,105),	 hypertension,	 livedo	 reticularis	251	
(70)),	liver	abnormalities	(hepatic	insufficiency	(70,72),	cholestatic	liver	(75)),	among	others.		252	
Biochemical findings: 253	
Primary	CoQ	deficiency	patients,	particularly	those	with	neonatal	onset,	can	show	higher	levels	254	
of	 lactate	 in	 plasma	 or	 serum.	 CoQ	 levels	 in	 skeletal	muscle	 biopsies	 or	 fibroblasts	may	 be	255	
reduced	(117),	as	well	as	the	enzymatic	activities	of	complex	I+III	and/or	II+III	(118).	256	
Pathogenesis 257	
The	 pathogenesis	 of	 CoQ	 deficiency	 is	 complex	 and	 not	 completely	 understood.	 The	258	
bioenergetic	defect	 and	 the	 increased	 reactive	oxygen	 species	 (ROS)	production	may	have	a	259	
crucial	role.	However	the	wide	spectrum	of	CoQ	functions,	the	unclear	roles	of	some	COQ	gene	260	
products	 and	 the	 considerable	 phenotypic	 variability,	 suggest	 that	 other	 mechanisms	261	
contribute	 to	 the	pathogenesis	of	 the	disease.	 In	cultured	cells	 it	has	been	 found	that,	while	262	
severe	CoQ	deficiencies	 lead	to	great	defects	 in	energy	production	with	no	major	 increase	 in	263	
oxidative	 stress,	 mild	 CoQ	 defects	 cause	 a	 significant	 increase	 in	 ROS	 production	 without	264	
affecting	 ATP	 production,	 but	 yielding	 increased	 cell	 death	 levels	 (119).	 In	 addition,	 as	265	
expected,	CoQ	deficiency	impairs	de	novo	pyrimidine	synthesis,	further	contributing	to	disease	266	
pathogenesis	(120).	CoQ	deficiency	cells	also	show	increased	mitophagy,	being	proposed	as	a	267	
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protective	 mechanism	 in	 disease	 pathogenesis	 (121),	 although	 other	 authors	 defined	 it	 as	268	
detrimental	 (122).	Recently,	 sulfide	oxidation	pathway	 impairment	has	been	proposed	as	 an	269	
additional	pathomechanism	in	primary	CoQ	deficiency,	as	different	in	vivo	and	in	vitro	models	270	
of	 the	 disease	 show	 a	 tissue-specific	 defect	 in	 the	 metabolism	 of	 H2S,	 leading	 to	 the	271	
accumulation	of	this	molecule,	that	may	alter	protein	S-sulfhydrilation,	inducing	changes	such	272	
as	 vasorelaxation,	 inflammation	 and	 ROS	 production	 (123).	 Finally,	 CoQ	deficiency	 has	 been	273	
linked	 to	 development	 of	 insulin	 resistance	 in	 human	 and	mouse	 adipocytes,	 as	 a	 result	 of	274	
increased	ROS	production	via	complex	II	(124).	275	
Genotype-phenotype correlation 276	
Due	to	the	small	number	of	patients	harbouring	mutations	in	COQ	genes	and	the	wide	range	of	277	
clinical	manifestations,	it	is	arduous	to	define	genotype-phenotype	correlations.	In	fact,	only	a	278	
few	families	with	pathogenic	variants	of	PDSS1,	PDSS2,	COQ5	or	COQ9	have	been	published,	279	
being	 unachievable	 to	 establish	 any	 correlation.	 In	 the	 case	 of	COQ9,	 studies	 in	 two	mouse	280	
models	 suggest	 that	 a	 key	 factor	 appears	 to	 be	 the	 different	 degree	 of	 impairment	 of	281	
formation	of	 the	CoQ	complex	 (49).	Even	 though	only	2	patients	with	COQ7	mutations	have	282	
been	described,	there	seems	to	be	a	correlation	between	the	residual	levels	of	CoQ	(and	levels	283	
of	COQ7	protein)	and	the	severity	of	the	disease:	fibroblasts	from	patient	with	the	most	severe	284	
phenotype	show	a	drastic	CoQ	deficiency	(101),	while	the	patient	with	the	milder	phenotype	285	
has	a	30%	decrease	in	CoQ	levels	in	skin	fibroblasts	(102).	Interestingly,	only	fibroblasts	with	a	286	
severe	 deficiency	 benefit	 from	 2,4-dihydroxybenzoic	 acid	 (2,4-dHB)	 supplementation,	 while	287	
CoQ	biosynthesis	was	inhibited	in	those	with	the	milder	defect	treated	with	2,4-dHB.			288	
COQ8A	and	COQ8B	have	the	highest	number	of	families	with	pathogenic	variants	reported	(29	289	
and	38),	 and	 in	neither	 case	 there	 is	 any	 correlation	between	 the	mutations	and	 the	clinical	290	
phenotype	(84,112).	In	the	case	of	COQ2	patients	(18	families	described),	who	show	the	widest	291	
clinical	 spectrum,	 it	 has	 been	 proposed	 that	 the	 severity	 of	 the	 disease	 correlates	 with	 the	292	
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enzymatic	residual	activity	and	hence	CoQ	 levels,	as	shown	by	expressing	mutant	proteins	 in	293	
yeast	 (125).	 It	 is	 worth	 to	mention	 that	most	 of	 the	COQ6	 patients	 were	 diagnosed	 during	294	
screening	for	SNRS,	so	there	may	be	a	reference	bias	in	these	cases	(71,107,109).	To	date,	no	295	
other	clear	correlations	have	been	observed	for	COQ4	patients.		296	
Diagnosis 297	
The	 diagnosis	 of	 primary	 CoQ	 deficiency	 is	 established	 with	 the	 identification	 of	 biallelic	298	
pathogenic	variants	in	any	of	the	genes	coding	for	one	of	the	proteins	directly	involved	in	CoQ	299	
biosynthesis.	Genome	or	specific	gene	sequencing	is	performed	when	decreased	levels	of	CoQ	300	
or	 reduced	 combined	 activities	 of	 complex	 I+III	 and	 II+III	 in	mitochondria	 of	 skeletal	muscle	301	
biopsies	are	detected	in	patients	(126,127).	It	is	important	to	note	that	biochemical	analysis	is	302	
not	 able	 to	 distinguish	 between	 primary	 and	 secondary	 CoQ	 deficiencies	 (127).	 Genetic	303	
identification	of	new	pathogenic	variants	is	usually	followed	by	functional	validation.	304	
CoQ	 levels	 can	 also	 be	 measured	 on	 plasma	 samples,	 white	 blood	 cells	 or	 skin	 fibroblasts	305	
obtained	after	skin	biopsy	from	patients	(128).	However,	there	are	concerns	about	CoQ	plasma	306	
measurements	 for	 diagnosis,	 since	 it	 seems	 to	 be	 influenced	 by	 the	 amount	 of	 plasma	307	
lipoproteins	 (carriers	 of	 CoQ	 in	 circulation)	 and	 the	 dietary	 intake.	 Muscle	 or	 fibroblasts	308	
represent	 the	 preferred	 diagnosis	 tissues,	 although	 sometimes	 fibroblasts	 	 do	 not	 show	309	
reduction	while	muscle	does	(129).It	has	been	shown	that	white	blood	cells	CoQ	levels	alone	310	
are	not	reliable	to	diagnose	primary	CoQ	deficiency	in	the	setting	of	nephrotic	syndrome	(76).	311	
De	novo	synthesis	can	also	be	measured	by	radioactive	precursor	 incorporation	in	fibroblasts	312	
(130)	which	 is	especially	useful	 to	discriminate	between	primary	and	 secondary	deficiencies.	313	
Recently,	urine	CoQ	measurement	as	non-invasive	approach	has	been	proposed	(131)	.		314	
Management 315	
Considering	 the	 wide	 clinical	 spectrum	 of	 this	 condition,	 any	 individual	 with	 a	 diagnosis	 of	316	
primary	CoQ	deficiency	should	be	assessed,	 in	order	 to	establish	 the	severity	of	 the	disease.	317	
14	
	
Importantly,	 a	 genetic	 consultation	 is	 recommended	 for	 other	 family	 members	 and	 for	318	
recurrence	 risk	of	patient’s	parents.	 	Based	on	 the	genetic	defect	 identified	 in	 the	patient,	a	319	
specific	follow-up	should	be	programmed.		320	
Being	 CNS	 manifestations	 very	 frequent,	 every	 patient	 with	 a	 diagnosis	 of	 CoQ	 deficiency	321	
should	undergo	periodical	neurological	examinations,	even	if	normal	at	diagnosis.	 In	fact,	the	322	
age	of	onset	of	these	symptoms	is	highly	variable,	ranging	from	the	first	hours	or	days	of	 life	323	
(as	 in	patients	with	COQ4	mutations),	 up	 to	 the	 seventh	decade	of	 life	 (as	 in	COQ2	 patients	324	
with	 the	adult-onset	multisystem	atrophy-like	phenotype).	 Evaluation	 should	 include	an	EEG	325	
analysis	 and	 a	 brain	MRI.	 In	 addition,	 peripheral	 nervous	 system	 should	be	 assessed	 for	 the	326	
possible	presence	of	peripheral	neuropathy	in	patients	with	PDSS1	and	COQ7	mutations.	327	
Patients	with	mutations	 in	PDSS1,	PDSS2,	COQ2,	COQ6,	COQ7,	COQ8A	and	COQ8B	may	have	328	
eye	 involvement	 due	 to	 optic	 atrophy,	 retinopathy,	 retinitis	 pigmentosa	 and	 even	 cataracts	329	
and	 should	 therefore	 be	 screened	 at	 diagnosis	 and	 during	 the	 follow-up.	 	 Audiometry	 is	330	
necessary	 in	COQ6	 patients	who	 almost	 invariably	manifest	 SRNS,	 but	 should	 be	 performed	331	
also	in	patients	with	mutations	in	PDSS1,	COQ8A	and	COQ4	who	may	sometimes	manifest	this	332	
phenotype.	333	
Individuals	 harbouring	 mutations	 in	 COQ2,	 PDSS1,	 PDSS2,	 COQ6,	 and	 COQ8B	may	 manifest	334	
renal	 involvement	 with	 SRNS,	 whose	 onset	 may	 vary	 from	 early	 childhood	 to	 adolescence.	335	
Tubulopathy	has	been	 reported	 rarely.	These	patients	 thus	need	 to	undergo	periodical	 renal	336	
function	tests	with	urine	analysis	for	proteinuria	and	nephrological	evaluations	for	the	risk	of	337	
evolving	to	ESRD.		338	
A	cardiologist	examination	with	echocardiogram	should	be	performed	 in	patients	with	COQ4	339	
mutations	(who	may	present	with	a	severe	prenatal-onset	cardiomyopathy)	and	should	also	be	340	
considered	 in	 individuals	with	mutations	 in	PDSS1	 and	COQ8B	 to	 exclude	 the	 presence	 of	 a	341	
valvulopathy	or	septal	defects.		342	
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Treatment 344	
Barriers	 for	 tissues	CoQ	delivery	have	been	found	due	to	 its	high	molecular	weight	and	poor	345	
aqueous	 solubility,	 but	 at	 high	 doses,	 dietary	 supplementation	 increases	 CoQ	 levels	 in	 all	346	
tissues,	 including	 heart	 and	 brain,	 especially	 with	 certain	 formulations	 (132,133).	 It	 also	347	
increases	 in	 circulating	 low	 density	 lipoproteins	 (LDL),	 where	 it	 functions	 as	 an	 efficient	348	
antioxidant	 together	 with	 α-tocopherol	 (134,135).	 CoQ	 supplementation	 at	 high	 doses	 has	349	
been	 demonstrated	 to	 be	 effective	 for	 treatment	 of	 both	 primary	 and	 secondary	 CoQ	350	
deficiencies	(136).	It	is	crucial	to	start	the	supplementation	as	soon	as	possible	to	get	favorable	351	
outcomes	 and	 to	 limit	 irreversible	 damage	 in	 critical	 tissues	 such	 as	 the	 kidney	 or	 the	 CNS	352	
(126).	 Different	 doses	 of	 CoQ	 have	 been	 employed	 for	 the	 treatment	 of	 primary	 CoQ	353	
deficiencies,	ranging	from	5	mg/kg/day	(98)	to	30-50	mg/kg/day	for	both	adults	and	children	354	
(137)	 but	 in	mouse	models	 of	 this	 condition	 even	higher	 doses	 (up	 to	 200	mg/kg/day)	 have	355	
been	used	(138).	Except	for	COQ8A	patients,	most	individuals	with	primary	forms	show	a	good	356	
response	 to	 CoQ	 treatment,	 which	 is	 usually	 evident	 after	 10-20	 days	 (137).	 Different	357	
formulations	of	CoQ	are	now	available,	both	in	the	oxidized	and	the	reduced	forms,	although	358	
most	of	the	data	available	have	been	obtained	in	patients	treated	with	ubiquinone.		359	
Alternatively	 to	 CoQ10	 supplementation,	 some	 4-HB	 analogues	 have	 been	 proposed	 as	360	
potential	 bypass	 molecules	 with	 higher	 bioavailability	 than	 CoQ.	 These	 water-soluble	 CoQ	361	
head	precursors	would	bypass	enzymatic	steps	disrupted	by	mutations	in	COQ	genes,	but	their	362	
efficacy	 may	 differ	 depending	 on	 the	 stability	 of	 the	 CoQ	 biosynthetic	 complex.	 Some	363	
examples	 are	 vanillic	 acid	 (VA)	 and	 3,4-dihydroxybenzoate	 (3,4-dHB),	 able	 to	 bypass	 COQ6	364	
mutations,	or	2,4-dHB	for	COQ7	defects	(figure	2C	and	2D).	The	effectivity	of	VA	and	3,4-dHB	365	
in	restoring	CoQ	biosynthesis	has	been	demonstrated	in	coq6	yeast	mutant	strains	expressing	366	
pathogenic	 versions	 of	 human	 COQ6	 (111).	 Notably,	 VA	 also	 stimulates	 CoQ	 synthesis	 and	367	
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improves	 cell	 viability	 in	 COQ9	 patient	 fibroblasts	 (139).	 2,4-dHB	 was	 able	 to	 increase	 CoQ	368	
levels	 and	 lifespan	 in	 Coq7	 (140)	 and	 Coq9	 defective	 mice	 (49),	 as	 well	 as	 to	 bypass	 the	369	
reaction	 in	 human	 fibroblasts	 with	 COQ7	 (101,102,139)	 and	 COQ9	 mutations	 (139).	370	
Remarkably,	the	effectivity	of	2,4-dHB	depends	on	the	nature	of	the	COQ7	mutation	and	the	371	
residual	activity	of	the	protein	(102).	It	has	also	been	reported	that	treatment	with	high	doses	372	
of	4-HB,	thus	increasing	COQ2	substrate	availability,	restores	CoQ	synthesis	in	COQ2	deficient	373	
cell	lines,	which	also	suggests	that	these	enzyme	variants	retain	some	residual	activity	(141).	374	
Early	onset	CoQ	deficiencies	can	cause	mortality	 in	 few	days.	We	have	observed	 that	CoQ	 is	375	
efficiently	incorporated	in	different	tissues	by	breastfeeding	and	placenta	in	mice	(unpublished	376	
data).	We	propose	treatment	of	pregnant	mothers	of	high-risk	newborns	(high	probability	of	377	
CoQ	deficiency	after	genetic	screening	or	due	to	family	history)	with	CoQ	supplementation,	in	378	
order	 to	 reduce	 tissue	 damage	 during	 embryonic/fetal	 development	 and	 to	 increase	 the	379	
survival	of	newborns	until	they	can	be	fed	with	supplements.	380	
Secondary deficiencies 381	
CoQ	levels	can	also	be	reduced	secondary	to	conditions	not	directly	linked	to	CoQ	biosynthesis,	382	
but	 related	 to	 oxidative	 phosphorylation	 (OXPHOS),	 other	 non-OXPHOS	 mitochondrial	383	
processes,	 or	 even	 to	 non-mitochondrial	 functions	 (142).	 Remarkably,	 secondary	 CoQ	384	
deficiencies	 are	 proved	 to	 be	 more	 common	 than	 primary	 deficiencies	 (142,143),	 probably	385	
because	 of	 the	 diversity	 of	 biological	 functions	 and	 metabolic	 pathways	 in	 which	 CoQ	 is	386	
involved	 in	 mitochondrial	 and	 non-mitochondrial	 membranes,	 highlining	 the	 importance	 of	387	
CoQ	homeostasis	 in	human	health.	However,	there	 is	a	 lack	of	consistency	of	CoQ	deficiency	388	
presence	 among	 different	 patients,	 which	 could	 suggest	 different	 susceptibility	 to	 the	389	
development	of	secondary	deficiencies	among	different	individuals.	Currently,	there	is	not	any	390	
general	 explanation	 for	 this,	 although	 genetic	 factors,	 such	 as	 certain	 polymorphisms,	 have	391	
been	 proposed	 to	 be	 involved	 (112,142–144).	 A	 comprehensive	 analysis	 of	 muscle	 and	392	
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fibroblasts	samples	from	patients	affected	by	a	wide	range	of	mitochondrial	diseases,	showed	393	
that	 secondary	 deficiencies	 were	 more	 frequent	 in	 depletion	 syndromes	 than	 in	 any	 other	394	
mitochondrial	disease	(142),	supporting	previous	observations	(145).	The	same	study	analysed	395	
CoQ	levels	 in	samples	of	patients	affected	by	different	OXPHOS	diseases,	but	were	unable	to	396	
find	 any	difference	between	 them.	 Further	 studies	on	wider	 cohorts	 are	needed	 in	order	 to	397	
understand	whether	certain	diseases	are	more	prone	to	develop	secondary	deficiencies	than	398	
others,	 as	 well	 as	 the	 underlying	 molecular	 mechanism.	 Nonetheless,	 it	 is	 clear	 that	399	
mitochondrial	 myopathies	 are	 frequently	 associated	 with	 CoQ	 secondary	 deficiencies	 (144).	400	
Besides	 its	 reduction	 in	 many	mitochondrial	 OXPHOS	 disorders,	 other	 diseases	 may	 display	401	
secondary	CoQ	deficiency,	including	ataxia	and	oculomotor	apraxia	syndrome	(MIM	#208920),	402	
multiple	acyl-CoA	dehydrogenase	deficiency	 (MIM	#231680),	cardiofaciocutaneous	syndrome	403	
(MIM	 #115150),	 methylmalonic	 aciduria	 (#	 251000),	 GLUT-1	 deficiency	 syndrome	 (MIM	404	
#606777),	 mucopolysaccharidosys	 type	 III	 (MIM	 #605270)	 or	 multisystem	 atrophy	405	
(142,143,146).	 The	mechanisms	 underlying	 CoQ	 secondary	 defects	 remain	 largely	 unknown,	406	
but	several	explanations	have	been	proposed	that	are	related	to:	(i)	an	increased	rate	of	CoQ	407	
degradation	 due	 to	 oxidative	 damage	 caused	 by	 a	 non-functional	 respiratory	 chain;	 (ii)	 a	408	
decrease	in	CoQ	through	the	interference	with	the	signalling	pathways	involved	in	the	process	409	
of	 biosynthesis;	 (iii)	 the	 reduction	 of	 the	 stability	 of	 the	 CoQ	 biosynthetic	 complex	 or	 (vi)	 a	410	
general	deterioration	of	mitochondrial	function	(142,143).	411	
In	addition,	CoQ	seems	to	be	reduced	in	the	process	of	aging	(147)	and	a	secondary	deficiency	412	
of	 CoQ	 	 may	 be	 a	 side	 effect	 of	 hypercholesterolemia	 treatment	 with	 statins,	 since	 both	413	
cholesterol	and	CoQ	share	part	of	their	biosynthetic	pathways		(148,149).	414	
Of	 course,	 particular	 symptoms	 of	 secondary	 CoQ	 deficiencies	 are	 highly	 dependent	 on	 the	415	
original	 pathology.	 Myopathies	 presented	 as	 muscular	 weakness,	 hypotonia,	 exercise	416	
intolerance	or	myoglobinuria	are	commonly	 reported	as	muscular	manifestations	 in	diseases	417	
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associated	 to	 secondary	 CoQ	 deficiencies.	 Neurological	 decline	 and	 ataxia	 are	 also	 often	418	
reported	 (143,150).	 It	 is	 possible	 that	 the	primary	disease	 symptoms	are	potentiated	by	 the	419	
lack	 of	 CoQ	 (143).	 In	 fact,	 many	 of	 these	 patients	 partially	 improve	 their	 condition	 by	 CoQ	420	
supplementation,	 which	 supports	 the	 importance	 of	 an	 early	 diagnosis	 also	 in	 these	 cases	421	
(150).	From	the	point	of	view	of	the	molecular	diagnosis,	 it	 is	necessary	to	perform	a	genetic	422	
analysis	to	distinguish	between	primary	and	secondary	deficiencies	(126).	423	
Concluding remarks 424	
The	 deficiency	 in	 CoQ	 is	 a	 genetically	 and	 clinically	 heterogeneous	 syndrome.	 Primary	425	
deficiency	 diagnosis	 is	 a	 great	 challenge	 due	 to	 the	 number	 of	 genes	 involved,	 the	 poor	426	
knowledge	 of	 CoQ	 biosynthesis	 pathway	 and	 its	 regulation	 in	 humans,	 the	 small	 number	 of	427	
patients	 described	 and	 the	 great	 variety	 of	 associated	 symptoms.	 Moreover,	 secondary	428	
deficiencies	can	be	consequences	of	many	other	mitochondrial	dysfunctions	adding	a	layer	of	429	
complexity	to	the	diagnosis.		Observation	of	the	clinical	manifestations	here	described	and	/or	430	
the	 molecular	 identification	 of	 potentially	 pathological	 variants	 of	 COQ	 genes	 should	 be	431	
complemented	by	the	biochemical	determination	of	CoQ	 levels,	biosynthesis	 rate	 if	possible,	432	
and	the	combined	enzymatic	activities	of	complexes	 I+III	and	 I+II	 in	muscle	or	fibroblast.	 It	 is	433	
important	 to	 identify	 potential	 cases	 as	 early	 as	 possible	 because	 high-dose	 CoQ	 oral	434	
supplementation	 is	a	very	effective	 treatment	 in	most	cases,	blocking	 the	progression	of	 the	435	
disease.	436	
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Summary 882	
• CoQ	is	an	endogenously	synthesized	lipid	that	is	essential	for	the	electron	transport	in	883	
the	mitochondrial	respiratory	chain.	884	
• Primary	CoQ	deficiencies	are	 rare	diseases	caused	by	mutations	 in	genes	of	 the	CoQ	885	
biosynthesis	pathway.	886	
• CoQ	 deficiencies	 are	 characterized	 by	 reduced	 levels	 of	 CoQ	 affecting	 energy	887	
production.	888	
• Primary	CoQ	deficiencies	 show	highly	heterogeneous	manifestations	mainly	affecting	889	
CNS,	PNS,	sensory	organs,	kidney,	skeletal	muscle	and	heart.	890	
• Currently,	 it	 is	 hard	 to	 establish	 any	 genotype-phenotype	 correlations	 for	 these	891	
diseases,	partially	due	to	the	low	amount	of	studied	patients.	892	
• 	It	 is	 essential	 to	biochemically	 determine	CoQ	deficiency	 since	 supplementation	has	893	
positive	therapeutic	effects.	894	
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Figure legends 896	
Figure1.	(A)	Chemical	structure	of	Coenzyme	Q	(CoQ)	and	(B)	redox	cycle	of	its	head	group.	(C)	897	
Integration	 of	 CoQ	 reduction	 by	 different	 dehydrogenases	 in	 the	 mETC.	 DHODH:	898	
Dihidroorotate	 dehydrogenase;	 G3PDH:	 Glycerol	 3	 phosphate	 dehydrogenase;	 ETF-FAD:	899	
Electron	 Transfer	 Flavoprotein;	 ETF-Qase:	 Electron	 Transfer	 Flavoprotein	 cCenzyme	 Q	900	
reductase;	 Cyt	 c:	 cytochrome	 c;	 SQR:	 sulphide-quinone	 oxidoreductase;	 PROD:	 	 	 proline	901	
dehydrogenase.	902	
Figure	 2.	 (A)	 Schematic	 model	 of	 human	 CoQ	 biosynthesis	 pathway.	 Blue	 arrows	 represent	903	
enzymatic	reactions	and	circled	numbers	represent	the	different	COQ	proteins	that	participate	904	
in	 each	 step.	 Brown	 arrows	 indicate	 regulatory	 mechanisms.	 Circled	 question	 mark	 shows	905	
currently	unidentified	enzymes.	(B)	Model	of	human	CoQ	biosynthetic	complex,	containing	at	906	
least	 COQ3-COQ9	 and	 lipids,	 such	 as	 CoQ	 itself.	 (C)	 and	 (D)	 green	 boxes	 contain	 4-HB	907	
analogues,	 defined	 as	 unnatural	 CoQ	precursors,	which	 are	 able	 to	 lead	 to	 CoQ	production,	908	
bypassing	defective	COQ	enzymes	such	as	COQ6	(3,4-dihydroxybenzoate	(3,4-dHB)	or	vanillic	909	
acid	 (VA))	 or	 COQ7	 (2,4-dihydroxybenzoate	 (2,4-dHB).	 COQ9	 patient	 fibroblasts	 can	 also	910	
benefit	 from	2,4-dHB	and	VA.	DDMQ:	demethoxy-demethyl-Coenzyme	Q;	DMQ:	demethoxy-911	
Coenzyme	Q;	DMeQ:	demethyl-Coenzyme	Q	912	
Figure	3.	Organs	and	systems	affected	in	 individuals	with	primary	CoQ	deficiency,	associating	913	
specific	 clinical	manifestations	with	 the	 genes	 involved	 in	 each	 one.	 For	 abbreviations	 go	 to	914	
Table	3.	For	frequency	of	each	symptom	linked	to	a	specific	gene	go	to	Table	2.	915	
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